Abstract:Middle East respiratory syndrome (MERS) is an acute, high-mortality-rate, severe infectious disease caused by an emerging MERS coronavirus (MERS-CoV) that causes severe respiratory diseases. The continuous spread and great pandemic potential of MERS-CoV make it necessarily important to develop effective vaccines. We previously demonstrated that the application of Gram-positive enhancer matrix (GEM) particles as a bacterial vector displaying the MERS-CoV receptor-binding domain (RBD) is a very promising MERS vaccine candidate that is capable of producing potential neutralization antibodies. We have also used the rabies virus (RV) as a viral vector to design a recombinant vaccine by expressing the MERS-CoV S1 (spike) protein on the surface of the RV. In this study, we compared the immunological efficacy of the vaccine candidates in BALB/c mice in terms of the levels of humoral and cellular immune responses. The results show that the rabies virus vector-based vaccine can induce remarkably earlier antibody response and higher levels of cellular immunity than the GEM particles vector. However, the GEM particles vector-based vaccine candidate can induce remarkably higher antibody response, even at a very low dose of 1 µg. These results indicate that vaccines constructed using different vaccine vector platforms for the same pathogen have different rates and trends in humoral and cellular immune responses in the same animal model. This discovery not only provides more alternative vaccine development platforms for MERS-CoV vaccine development, but also provides a theoretical basis for our future selection of vaccine vector platforms for other specific pathogens.

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Current Advancements and Potential Strategies in the Development of MERS-CoV Vaccines

Development of Middle East Respiratory Syndrome Coronavirus vaccines – advances and challenges

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

Antibodies And Vaccines Against Middle East Respiratory Syndrome Coronavirus

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development

Middle East Respiratory Syndrome: Current Status and Future Prospects for Vaccine Development

Advances in mRNA and other vaccines against MERS-CoV

Prospects for a MERS-CoV Spike Vaccine

Receptor-binding domain-based subunit vaccines against MERS-CoV.

Evaluation of candidate vaccine approaches for MERS-CoV

[Current Status of Middle East Respiratory Syndrome Vaccines].

Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies

Middle East respiratory syndrom: pathogenesis and therapeutic developments (vol 14, pg 237, 2019)

MERS-CoV spike protein: Targets for vaccines and therapeutics

From SARS to MERS: Evidence and Speculation

Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice

Bioinformatics Analysis on Potential Anti-Viral Targets Against Spike Protein of MERS-CoV

Middle East respiratory syndrome coronavirus and development of vaccines and specific drugs for its control

Research progress on human neutralizing monoclonal antibodies against Middle East respiratory syndrome coronavirus